drugset / Trial / NCT04625855

Study of the Absorption, Metabolism, and Excretion of [14C]-Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) Following a Single Oral Dose in Healthy Male Subjects

NCT04625855

Phase 1 Completed 8 enrolled Spero Therapeutics Covance · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the absorption, metabolism, and excretion of \[14C\]-TBPM-PI-HBr and to characterize and determine the metabolites present in plasma, urine, and where possible, feces in healthy male subjects following a single oral administration.

Timeline

Start
2020-09-30
Primary completion
2020-10-16
Completion
2020-10-16

Drugs

EvaluationDrugModalityDoseRoute
Subject TBPM-PI-HBr Small molecule 600 mg Oral

Indications

No indication recorded.